Meibomian gland dysfunction Eye Diseases
Conditions
Interventions
This study was conducted in a community Optometry practice over a 2 year period (2016-2018). Patients were invited to participate in the study, who had persistent Meibomian gland dysfunction (MGD) and
Sponsors
University of Dundee
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: This study was conducted in a community Optometry practice over a 2 year period (2016-2018). Patients were invited to participate in the study, who had persistent Meibomian gland dysfunction (MGD) and previous treatment of lid hygiene, lubricants, heat & massage had been ineffective at relieving signs or symptoms.
Exclusion criteria
Exclusion criteria: 1. No Meibomian gland dysfunction 2. Managed Meibomian gland dysfunction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Meibomian gland dysfunction (MGD) measured using the Efron grading scale before and after treatment 2. Fluorescein tear break up time (FTBUT) measured after instillation of 1% Fluorescein (Bausch & Lomb minims) and measured in seconds, counted by the examiner, before and after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Long-term benefit of treatment on symptoms and self-treatment methods, by post-treatment survey one year on from treatment. In brief, the survey asked the participants how their management of MGD had changed, which dry eye symptoms they had pre- and post-treatment (sensitivity to light, gritty/ burning sensation and blurred vision). They were also asked to what extent their symptoms affected their lifestyle, (reading, night driving, computer use and watching television) and how they were affected by environmental conditions (windy, dry and air-conditioned environments). This used a combination of yes/no responses and a numerical grading of symptoms of 1-5, where 1= least affected and 5=most affected. | — |
Countries
Scotland, United Kingdom
Contacts
Public ContactIan Jarvis
Outcome results
None listed